Telix Pharmaceuticals (ASX:TLX) has announced that the first Australian patient has been dosed in the international NOBLE Registry.
The global study aims to improve access for men to innovative prostate cancer imaging tools. The NOBLE Registry is co-supported by Telix and Brussels-based Oncidium Foundation.
The NOBLE Registry is collecting clinical data to inform the development of TLX599-CDx, an investigational prostate cancer imaging agent that targets PSMA (prostate specific membrane antigen) using single-photon emission computed tomography (SPECT).
The Australian arm of the NOBLE study is being led by PhD researcher Peter Tually at TeleMed, in collaboration with Clinical Professor Nat Lenzo and Professor Geoff Currie at Charles Sturt University (CSU), and will recruit prostate cancer patients in the Kalgoorlie, Albany and Geraldton regions in rural Western Australia.
Telix said it is developing TLX599-CDx as an accessible alternative, particularly for certain countries as well as remote and rural locations where SPECT is the predominant imaging modality.
According to Peter Tually, “Our mission is to bring a metropolitan standard of care to the bush and level the playing field where we can. Our involvement in NOBLE takes us a step closer to achieving this, by giving patients local access to the latest prostate cancer imaging tools which could have a profound impact on clinical decisions regarding their treatment.”
Professor Currie said the project “is consistent with CSU leadership in rural health and commitment to addressing social asymmetry, inequity and injustice of health-related outcomes.”
Telix CEO Dr Christian Behrenbruch added, “The NOBLE study is an important piece of clinical research which could expedite access to PSMA imaging for patients who might otherwise have to travel long distances or endure significant wait times to access this technology. With the support of investigators such as Peter Tually and Professor Geoff Currie, and their global counterparts, we are recruiting patients at a steady pace, which will pave the way for greater access to PSMA imaging for patients in developing nations, rural and remote areas – first on study use basis, but ultimately as a regulatory approved imaging agent.”